2021-10-28-上交所-浙江九洲药业股份有限公司2021年第三季度报告_15页_410kb

Summary of 2021 Q3 Report for浙江九洲药业股份有限公司

• Financial Performance: The company posted strong results in the third quarter of 2021. Revenue reached RMB 1.136 billion, marking a 53.97% increase in the quarter and 72.08% year-over-year growth. Net profit attributable to shareholders was RMB 198.3 million, up by 80.39% quarter-on-quarter and 97.65% year-over-year, driven primarily by CDMO business expansion. Key financial metrics show improvement, including a rise in basic and diluted earnings per share by 71.43% and 90.00% year-to-date.

• Key Business Drivers: The increase in revenues and profits is mainly attributed to CDMO services. Operating activities generated positive cash flow, with a 15.03% year-over-year increase in operating cash flow.

• Shareholder and Governance: The report includes shareholder details, with top shareholders remaining largely unchanged but featuring increased holdings from key entities like浙江中贝九洲集团有限公司. Total assets rose to RMB 6.45 billion, reflecting growth.

• Significant Events: On July 16, 2021, the company received a RMB 50,000 penalty due to safety issues, but completed整改. In September, it acquired杭州珠联医药科技有限公司 for RMB 2.219 million through a wholly-owned subsidiary, expanding its pharmaceutical sector operations.

• Other Notes: The report addresses non-recurring items affecting earnings but emphasizes CDMO as the core growth area. Overall, financial indicators show robust performance across various metrics.